Informations générales (source: ClinicalTrials.gov)
Study of Gait and Posture in Subacute Acquired Neuropathies and in Hereditary Neuropathies (PONE)
Interventional
N/A
University Hospital, Lille (Voir sur ClinicalTrials)
mai 2021
décembre 2023
08 février 2025
If the classification between hereditary and acquired neuropathy is often easy, there is
no completely specific marker allowing the distinction between the two etiologies.
Clinical experience suggests that hereditary neuropathies have less impact on balance and
gait than the acquired neuropathies at equivalent level of impairment, but this has never
been clearly demonstrated.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hôpital Roger Salengro, CHU - Lille - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- CMT1A for molecular-proven Group 1 (PMP22 duplication)
- IPDC likely or defined for Group 2
- Able to walk 10 m unassisted
- CMT1A for molecular-proven Group 1 (PMP22 duplication)
- IPDC likely or defined for Group 2
- Able to walk 10 m unassisted
- Neurological history other than neuropathy: epilepsy, stroke, dementia
- Pregnant women
- Person under guardianship or trusteeship
- Musculoskeletal conditions other than neuropathy impairing walking abilities
- Major comorbidity considered a contraindication by the investigator (cancer,
unstable angor, etc.)